Potent and selective α1-adrenoceptor antagonist; hypotensive.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 405.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.47 mL||12.33 mL||24.66 mL|
|5 mM||0.49 mL||2.47 mL||4.93 mL|
|10 mM||0.25 mL||1.23 mL||2.47 mL|
|50 mM||0.05 mL||0.25 mL||0.49 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Chern et al (1993) Studies on quinazolines. 2,3-Dihydroimidazo[1,2c]quinazoline derivatives. A novel class of potent and selective α1-adrenoceptor antagonists and antihypertensive agents. J.Med.Chem. 36 2196 PMID: 8101878
If you know of a relevant reference for 2-MPMDQ, please let us know.
View Related Products by Product Action
Keywords: 2-MPMDQ, supplier, Potent, selective, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenoceptor, α1-adrenergic, alpha1-adrenergic, a1-adrenergic, antagonists, σ2, sigma2, ligand, Receptors, hypotensive, anti-hypertensive, Adrenergic, Alpha-1, Receptors, Tocris Bioscience
Citations for 2-MPMDQ
Citations are publications that use Tocris products.
Currently there are no citations for 2-MPMDQ. Do you know of a great paper that uses 2-MPMDQ from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.